{"drugs":["Alphanine SD","Factor IX Human, Purified","Mononine"],"mono":{"0":{"id":"926613-s-0","title":"Generic Names","mono":"Factor IX Human, Purified"},"1":{"id":"926613-s-1","title":"Dosing and Indications","sub":{"0":{"id":"926613-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Hemophilia B - Hemorrhage:<\/b> number of Factor IX international units required = body weight (kg) times desired Factor IX increase (%) times 1 international unit\/kg<\/li><li><b>Hemophilia B - Hemorrhage:<\/b> Alphanine(R) SD: mild hemorrhage (20% to 30% of normal Factor IX level), 20 to 30 international units\/kg IV twice daily until hemorrhage stops and healing is achieved (1 to 2 days)<\/li><li><b>Hemophilia B - Hemorrhage:<\/b> Alphanine(R) SD: moderate hemorrhage (25% to 50% of normal Factor IX level), 25 to 50 international units\/kg IV twice a day until healing is achieved (2-7 days)<\/li><li><b>Hemophilia B - Hemorrhage:<\/b> Alphanine(R) SD: major hemorrhage (50% of normal Factor IX level), 30 to 50 international units\/kilogram IV twice a day for at least 3 to 5 days. Followed by 20 international units\/kg IV (20% of normal Factor IX level) twice a day. Treatment may need to be continued for up to 10 days<\/li><li><b>Hemophilia B - Hemorrhage:<\/b> Alphanine(R) SD: surgery (50% to 100% of normal Factor IX level), 50 to 100 international units\/kg IV twice daily for 7 to 10 days<\/li><li><b>Hemophilia B - Hemorrhage:<\/b> Mononine(R): mild hemorrhage (15% to 25% of normal Factor IX level), 20 to 30 international units\/kg IV once and repeated in 24 hours if needed<\/li><li><b>Hemophilia B - Hemorrhage:<\/b> Mononine(R): major trauma or surgery (25% to 50% of normal Factor IX level), up to 75 international units\/kg IV every 18 to 30 hours up to 10 days if needed<\/li><\/ul>"},"1":{"id":"926613-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Hemophilia B - Hemorrhage:<\/b> number of Factor IX international units required = body weight (kg) times desired Factor IX increase (%) times 1 international unit\/kg<\/li><li><b>Hemophilia B - Hemorrhage:<\/b> Mononine(R): mild hemorrhage (15% to 25% of normal Factor IX level), 20 to 30 international units\/kg IV once and repeated in 24 hours if needed<\/li><li><b>Hemophilia B - Hemorrhage:<\/b> Mononine(R): major trauma or surgery (25% to 50% of normal Factor IX level), up to 75 international units\/kg IV every 18 to 30 hours up to 10 days if needed<\/li><\/ul>"},"3":{"id":"926613-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Hemophilia B - Hemorrhage<br\/>"}}},"3":{"id":"926613-s-3","title":"Contraindications\/Warnings","sub":[{"id":"926613-s-3-9","title":"Contraindications","mono":"hypersensitivity to mouse proteins <br\/>"},{"id":"926613-s-3-10","title":"Precautions","mono":"<ul><li>disseminated intravascular coagulation (DIC); risk of thromboembolic complications<\/li><li>factor IX inhibitors, development of; increased risk for hypersensitivity reaction, including anaphylaxis<\/li><li>fibrinolysis; risk of thromboembolic complications<\/li><li>high doses; greater risk of myocardial infarction, disseminated intravascular coagulation, venous thrombosis and pulmonary embolism<\/li><li>human plasma contained in medication; potential risk for transmission of infection, including theoretical risk for transmission of Creutzfeldt-Jakob disease<\/li><li>hypersensitivity reactions, including anaphylaxis; reported for all factor IX products<\/li><li>immune tolerance induction, attempted in patients with factor IX inhibitors and a history of allergic reactions; potential risk for nephrotic syndrome<\/li><li>liver disease; increased risk of thromboembolic complications<\/li><li>major deletion mutations of factor IX gene; increased risk of inhibitor formation and acute hypersensitivity reaction<\/li><li>neonates; increased risk of thromboembolic complications<\/li><li>post-operative patients; increased risk of thromboembolic complications<\/li><li>thromboembolic phenomena; increased risk of thromboembolic complications<\/li><\/ul>"},{"id":"926613-s-3-11","title":"Pregnancy Category","mono":"Factor IX: C (FDA)<br\/>"},{"id":"926613-s-3-12","title":"Breast Feeding","mono":"<ul><li>Factor IX: WHO: Compatible with breastfeeding.<\/li><li>Factor IX: Micromedex: Infant risk is minimal.<\/li><\/ul>"}]},"5":{"id":"926613-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Flushing, Injection site pain, Injection site reaction<\/li><li><b>Gastrointestinal:<\/b>Nausea, Taste sense altered<\/li><li><b>Neurologic:<\/b>Dizziness, Headache<\/li><\/ul><b>Serious<\/b><ul><li><b>Hematologic:<\/b>Thromboembolic disorder<\/li><li><b>Immunologic:<\/b>Allergic reaction to drug, Anaphylaxis<\/li><li><b>Renal:<\/b>Nephrotic syndrome<\/li><li><b>Respiratory:<\/b>Dyspnea<\/li><li><b>Other:<\/b>Angioedema<\/li><\/ul>"},"6":{"id":"926613-s-6","title":"Drug Name Info","sub":{"0":{"id":"926613-s-6-17","title":"US Trade Names","mono":"<ul><li>Mononine<\/li><li>Alphanine SD<\/li><\/ul>"},"2":{"id":"926613-s-6-19","title":"Class","mono":"Antihemophilic Agent<br\/>"},"3":{"id":"926613-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"926613-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"926613-s-7","title":"Mechanism Of Action","mono":"Overall, all forms of factor IX achieve hemostasis through the same mechanism.  A complex of factor VII and tissue factor (via the extrinsic coagulation pathway) and factor XIa (via the intrinsic pathway) activate factor IX which, in combination with factor VIII:C, activates factor X to Xa. Through this pathway, prothrombin is converted to thrombin which, in turn, converts fibrinogen to fibrin.<br\/>"},"8":{"id":"926613-s-8","title":"Pharmacokinetics","sub":{"4":{"id":"926613-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Mononine(R): 23 to 31 hours<\/li><li>Alphanine(R) SD: 21 hours<\/li><li>Solvent detergent treated products: 19 hours<\/li><\/ul>"}}},"9":{"id":"926613-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>warm to room temperature<\/li><li>use double-ended needle to transfer diluent (provided) to single-dose vial; direct flow of diluent against side of vial<\/li><li>let vial stand until contents are in solution and then swirl gently; do NOT shake; do NOT invert vial until ready to withdraw contents<\/li><li>use as soon as possible (within 3 h) after reconstitution; discard unused portion<\/li><li>using microaggregate filter (provided), withdraw dose into syringe; discard filter<\/li><li>administer Mononine(R) by slow infusion at a rate approximately 2 mL\/min; administer Alphanine(R) SD at a rate not to exceed 10 mL\/min<\/li><\/ul>"},"10":{"id":"926613-s-10","title":"Monitoring","mono":"<ul><li>normalization of coagulation parameters<\/li><li>factor IX assays at least once daily prior to infusion; in patients with severe hemorrhage or undergoing major surgery<\/li><li>early signs and symptoms of hypersensitivity reactions; especially in patients with major deletion mutations in the factor IX gene, rate of administration may need to be adjusted and\/or therapy discontinued<\/li><li>signs and symptoms of infection; human plasma derived product and theoretical risk of infection including viruses and Creutzfeldt-Jakob disease agent<\/li><li>signs and symptoms of thrombosis, disseminated intravascular coagulation; especially in patients with known liver disease, surgical patients, neonates, and patients with risk factors predisposing to thrombosis<\/li><\/ul>"},"11":{"id":"926613-s-11","title":"How Supplied","mono":"<ul><li><b>Alphanine SD<\/b><br\/>Intravenous Powder for Solution: 1 IU<br\/><\/li><li><b>Mononine<\/b><br\/>Intravenous Powder for Solution: 1 IU<br\/><\/li><\/ul>"}}}